Methods for treating uterine disorders

Details Methods for treating uterine disorders Methods for treating uterine disorders

2003-03-03

2011-12-06

Rawlings, Stephen (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S001100, C514S012100, C514S018100, C514S018800, C530S300000, C530S350000

Reexamination Certificate

active

08071550

ABSTRACT:
A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue.

REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766606 (1998-06-01), Brady
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6261572 (2001-07-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6831059 (2004-12-01), Donovan
patent: A 61 K 7/32 (1998-11-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 99/03483 (1998-07-01), None
patent: WO 99/03483 (1999-01-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 00/10598 (2000-03-01), None
patent: WO 00/15245 (2000-03-01), None
patent: WO 00/24419 (2000-05-01), None
patent: WO 00/57897 (2000-10-01), None
patent: WO 00/62746 (2000-10-01), None
patent: WO 00/74703 (2000-12-01), None
patent: WO 01/21213 (2001-03-01), None
patent: WO 02/74327 (2002-03-01), None
Vilos (Minerva Ginecol. Oct. 2003; 55 (5): 417-423).
Volpe et al. (Eur. J. Obstet. Gynecol. Reprod. Biol. May 10, 1991; 39 (3): 223-225).
Dqani et al. (Acta Obstet. Gynecol. Scand. Jan. 1998; 77 (1): 74-77).
Wiznitzer et al. (Biochem. Biophys. Res. Commun. May 16, 1988; 152 (3): 1326-1331).
Sion-Vardi et al. (J. Urol. Nov. 1992; 148 (5): 1568-1570).
Eidne et al. (J. Clin. Endocrinol. Metab. Mar. 1987; 64 (3): 425-432).
Bramley et al. (Placenta. Oct. 1994; 15 (7): 733-745).
Laske et al. (J. Neurosurg. Mar. 1994; 80 (3): 520-526).
Hoffman et al. (Head Neck. Mar. 1997; 19 (2): 92-97).
Chegini et al. (J. Clin. Endocrinol. Metab. Sep. 1996; 81 (9): 3215-3221).
Dong et al. (Mol. Hum. Reprod. Sep. 1998; 4 (9): 893-898).
Raga et al. (Biol. Reprod. Sep. 1998; 59 (3): 661-669).
Koticha et al. (J. Cell Sci. Aug. 15, 2002; 115 (Pt 16): 3341-3351).
Morris et al. (Am. J. Physiol. Heart Circ. Physiol. Dec. 2002; 283 (6): H2627-H2635).
Vazquez-Martinez et al. (Endocrinology. Dec. 2001; 142 (12): 5364-5370).
Chaddock et al. (Infect. Immun. May 2000; 68 (5): 2587-2593).
Ahnert-Hilger et al. (Eur. J. Neurosci. Mar. 1998; 10 (3): 1145-1152).
Blasi et al. (Nature. Sep. 9, 1993; 365 (6442): 160-163).
Graham et al. (Ann. N. Y. Acad. Sci. Oct. 2002; 971: 210-221).
Jongerius et al. (Laryngoscope. Jan. 2003; 113 (1): 107-111).
Andrews et al. (Surg. Endosc. Aug. 1999; 13 (8):742-746).
Quintanar et al. (Endocr. Regul. Mar. 2004; 38 (1): 1-6).
Wilson et al. (Expert Opin. Investig. Drugs. Nov. 2007; 16 (11): 1851-1863).
Ramakrishnappa et al. (Anim. Reprod. Sci. Aug. 2005; 88 (1-2): 95-113).
Li et al. (Protein Eng. 2002; 15 (5): 419-427).
Emons et al. (J. Clin. Endocrinol. Metab. Dec. 1993; 77 (6): 1458-1464).
Anderson, Johan et al., Differential sorting of SNAP-25a and SNAP-25b proteins in neuroblastoma cells;European Journal of Cell Biology; 79, Nov. 2000; pp. 781-789.
Balakina, G.B. et al.,Arkh Anat Gistof Embriol; 1986; 90(4); pp. 73-77 No Translation.
Blasl, Juan et al., Botuligum neurotoxin A selectively cleaves the synaptic protein SNAP-25;Nature; vol. 365; Sep. 9, 1993; pp. 160-162.
Boyd, Robert S. et al., The Effect of Botulinum Neurotoxins on the Release of Insulin from the Insulinoma Cell Lines HIT-15 and TINm5F(*); Abstract; JBC Online 270(31); 18216.
Cabello, Gertrudis et al., A Rat Mammary Tumor Model Induced by the Organophosphorous Pesticides Parathion and Malathion, Possibly through Acetycholinesterase Inhibition;Environmental Health Perspectives; vol. 109; No. 5; May 2001; pp. 471-479.
Coffey, Robert J. et al., Stereotactic and Diagnostic Imaging: Methods of Correlation with Traditional Stereotactic Atlases;A Neuroimaging Atlas for Surgery of the Brain Including Radiosurgery and Stereotaxis; Published by Lippincott—Raven, Philadelphia/New York; pp. 1-7.
Cukan, Michael C. et al., Expression of SNAP-23 and SNAP-25 in the Pancreatic Acinar Tumor Cell Line AR42J;Molec Biol Cell; 1999; 20(Suppl); 398a; # 2305.
Dayanithi, G. et al., Release of Vasopressin From Isolated Permeabilized Neurosecretory Nerve Terminals is Blocked by the Light Chain of Botulinum A Toxin;Neuroscience; 1990; 39(3) pp. 711-715.
Der, Roger et al., Gastric Neoplasms; Gastrointestinal Pathology; by Parakrama Chandrasoma, MD, MRCP (UK); pp. 105-144.
Doggweiler, R. et al., Botulinum Toxin Type A Causes Diffuse and Highly Selective Atrophy of Rat Prostate;J. Urol; 157(4) Suppl. Abstr 666, 1997 p. 363.
Dorosevich, A.E. et al.,Arkh Patol; 1994; 56(6); pp. 49-53.
Duggan, Michael J. et al., A survey of botulinum neurotoxin substrate expression in cells;Mov Disord; May 1995; 10(3) p. 376.
Ellis, I.O. et al., Tumors of the breast;Diagnostic Histopathology of Tumorsvol. 1 edited by Christopher D.M. Fletcher; pp. 865-930.
Fabian, Carol J. et al., Beyond Tamoxifen New Endpoints for Breast Cancer Chemoprevention, New Drugs for Breast Cancer Prevention;Annals N Y Academy of Sciences; 2001; 952; pp. 44-59.
Goodall, Anna R. et al., Occurrence of Two Types of Secretory Vesicles in the Human Neuroblastoma SH-SY5Y;Journal of Neurochemistry; vol. 68, No. 4,1997, pp. 1542-1552.
Graff, Lothar et al., Expression of Vesicular Monoamine Transporters, Synaptosomal-associated Protein 25 and Syntaxinl;Cancer Research; 61 (5); 2138 Abstract.
Grosse, J. et al., Synaptosome-Associated Protein of 25 Kilodaltons in Oocytes and Steroid-Producing Cells of Rat and Human Ovary: Molecular Analysis and Regulation by Gonadotropins;Biology of Reproduction; 63, 2000; pp. 643-650.
Hohne-Zell, Barbara et al., Functional Importance of Synaptobrevin and SNAP-25 during Exocytosis of Histamine by Rat Gastric Enterochromaffin-Like Cells; ENDO; 1997; vol. 138, No. 12; pp. 5518-5526.
Huang, X., et al., Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insul secretion from HIT-T15 insulinoma cells,Molecular Endocrinology, 12(7):1060-1070.
Lawrence, G.W., et al., Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-assocated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B,Eur J.Biochem, Mar. 15, 1996;236(3):877-86.
Lidbeck, J, Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications,Pain Res Manage, vol. 7 No. 2 Summer 2002, pp. 81-92.
Maksymowych, A.B., et al., Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells,J Biol ChemAug. 1998 273(34):21950-21957.
Meyer, K.E., A comparative systemic toxicity study of neurobloc in adult and juvenile cynomolgus monkeys,Mov Disord2000;15(suppl 2):54.
Morlin, B., et al., Does nitric oxide act as a cellular messenger in muscarinic endometrial secretion in the guinea-pig?,Acta Physiol Scand, 2002, 174, 311-315.
Morris, J.L., Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons,Am J Physiol Heart Circ Physiol, Dec. 2002; 283(6):H2627-35.
Oyler, G.A., Distribution and expression of SNAP-25 immunoreactivity in rat brain, rat PC-12 cells and human SMS-KCNR neuroblastoma cells,Developmental Brain Research, 65 (1992) 133-146.
Panagiotou, S., et al., Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements,Journal of Cellular Biochemistry, 73:204-211 (1999).
Pesic, S., et al., Acetylcholine-induced contractions in the porcine internal mammary artery: possible role of muscarinic receptors,J. Vet Med A46, 509-515 (1999).
Sadoul, K., et al., SNAP-25 is expressed in islets of langerhans and is involved in insulin release,The Journal of Cell Biology, vol. 128, 1995, 1019-1028.
Seneviraine, S., Botox and the management of pectoral spasm after subpectoral implant insertion,Plast Reconstr Surg, Jul. 2000;106(1):224-225.
Shukla, A., et al., SNAP-25 associated

Affiliated with

Also associated with

Rating

Methods for treating uterine disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating uterine disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating uterine disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307332